Dr. Goriounova successfully defended her thesis, “ELD607 is a novel, specific Orai1 inhibitor,” on May 10.
Her PhD Advisor was Dr. Robert Tarran.
Dr. Goriounova will be starting a position at Priovant Therapeutics as an Early Development Clinical Pharmacology Fellow. Priovant is a clinical stage company developing the anti-inflammatory Brepocitinib for orphan diseases.
Publications
Goriounova AS, Gilmore RC, Wrennall JA, Tarran R. Super resolution microscopy analysis reveals increased Orai1 activity in asthma and cystic fibrosis lungs. J Cyst Fibros. 2023 Jan;22(1):161-171. doi: 10.1016/j.jcf.2022.07.003. Epub 2022 Aug 10. PMID: 35961837; PMCID: PMC9982747.
Wu T, Goriounova AS, Worthington EN, Wrennall JA, Ghosh A, Ahmad S, Flori Sassano M, Tarran R. SPLUNC1 is a negative regulator of the Orai1 Ca2+ channel. Physiol Rep. 2022 May;10(10):e15306. doi: 10.14814/phy2.15306. PMID: 35581745; PMCID: PMC9114653.
Wrennall JA, Ahmad S, Worthington EN, Wu T, Goriounova AS, Voeller AS, Stewart IE, Ghosh A, Krajewski K, Tilley SL, Hickey AJ, Sassano MF, Tarran R. A SPLUNC1 Peptidomimetic Inhibits Orai1 and Reduces Inflammation in a Murine Allergic Asthma Model. Am J Respir Cell Mol Biol. 2022 Mar;66(3):271-282. doi: 10.1165/rcmb.2020-0452OC. PMID: 34807800; PMCID: PMC8937239.
Dr. Goriounova is starting a new position at Priovant Therapeutics as an Early Development Clinical Pharmacology Fellow. Priovant is a clinical stage company developing the anti-inflammatory Brepocitinib for orphan diseases.
UPDATE!
Below are pics from Sasha’s White Coat Ceremony after her PhD defense presentation when Henrik Dohlman presented her with her PHCO White Coat. (click for larger view)
We wish you all the best, Sasha!